- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00657644
Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction
December 23, 2014 updated by: Bayer
Open-label Multi-centre Non Randomised Study of Efficacy and Safety of Vardenafil (BAY 38-9456; SB-782528) Administered in Flexible-dose Regimen in Males With Erectile Dysfunction of Broad Aetiology.
To find out more information on how effective and safe vardenafil is at treating impotence in men living in Russia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation, 123367
-
Moscow, Russian Federation, 125101
-
Moscow, Russian Federation, 117997
-
Moscow, Russian Federation, 117837
-
Moscow, Russian Federation, 105425
-
Moscow, Russian Federation, 117198
-
Moscow, Russian Federation, 127206
-
St Petersburg, Russian Federation, 198013
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males with ED according to the NIH definition (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance) for at least 3 months.
- Heterosexual relationship
- Age range: 18 years and older
- Documented written Informed Consent
- The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary "Was sexual activity initiated with the intention of intercourse?") on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"] "Were you able to achieve at least partial erection (some enlargement of the penis)?", "Were you able to insert your penis in your partner's vagina?" and "Did your erection last long enough for you to have successful intercourse?".
Exclusion Criteria:
- Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
- Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) that in the opinion of the Investigator would significantly impair erectile function
- Primary hypoactive sexual desire
- Spinal cord injury
- History of surgical prostatectomy (excluding TURP).
- Retinitis pigmentosa
- History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.
- History of positive test for HIV.9. Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
- Clinically significant chronic hematological disease, which may lead to priapism such as sickle cell anemia and leukemia.
- Bleeding disorder.
- Significant active peptic ulceration.
- Unstable angina pectoris
- History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
- Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm).
- Resting hypotension (a resting systolic blood pressure of < 90 mm Hg) or hypertension (a resting systolic blood pressure > 170 mm Hg or a resting diastolic blood pressure > 110 mm Hg)
- NYHA Class III and IV heart failure
- Symptomatic postural hypotension within 6 months of visit 1.
- History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).
Concomitant Medication:
- Subjects who are taking nitrates or nitric oxide donors.
- Subjects who are taking anti-androgens
- Subjects who are taking androgens.
- Subjects who take anticoagulants, except for antiplatelet agents.
- Subjects who have received any investigational drug (including placebo) within 30 days of visit 1.6. Use of any treatment for ED within the 7 days of visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
- Subjects who are taking the following potent inhibitors of cytochrome P- 450 3A4: HIV protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
- Subjects who are taking alpha-blockers.
Abnormal Laboratory Values:
- Subjects who have a serum total testosterone level greater than 25% below the lower limit of normal according to the range of the testing laboratory
- Subjects with a serum creatinine >3.0 mg/dl
- Elevation of AST and/or ALT >3X the ULN.
- Diabetic subjects with an HbA1c >12%.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Erectile Function (EF) domain score
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Erectile Function (EF) domain score
Time Frame: Week 4, 8 and 12 Last Observation Carried Forward (LOCF)
|
Week 4, 8 and 12 Last Observation Carried Forward (LOCF)
|
Change from baseline of Erectile Function domain score
Time Frame: Week 4, 8 and 12 Last Observation Carried Forward (LOCF)
|
Week 4, 8 and 12 Last Observation Carried Forward (LOCF)
|
IIEF domain scores
Time Frame: Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)
|
Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)
|
Patient Diary Questions
Time Frame: Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)
|
Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)
|
Global Assessment Question (GAQ)
Time Frame: Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)
|
Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF)
|
Premature termination, adverse events, laboratory abnormalities and concomitant medication usage
Time Frame: Week 4, 8 and 12
|
Week 4, 8 and 12
|
Measurements and changes from baseline in vital signs, ECG cardiac cycle measurements and ECG heart rate
Time Frame: Week 12
|
Week 12
|
Haematology, Clinical Chemistry, Urinalysis
Time Frame: Week 12
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Primary Completion (Actual)
March 1, 2004
Study Completion (Actual)
March 1, 2004
Study Registration Dates
First Submitted
April 8, 2008
First Submitted That Met QC Criteria
April 11, 2008
First Posted (Estimate)
April 14, 2008
Study Record Updates
Last Update Posted (Estimate)
December 25, 2014
Last Update Submitted That Met QC Criteria
December 23, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11182 (DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Levitra (Vardenafil, BAY38-9456)
-
BayerCompleted
-
BayerGlaxoSmithKlineCompleted
-
BayerCompletedErectile DysfunctionBelgium, Finland, Germany, France, Denmark, United Kingdom, Spain
-
BayerCompletedErectile Dysfunction
-
BayerCompletedDepression | Erectile DysfunctionItaly, Spain, France, United States, Canada
-
BayerCompletedErectile DysfunctionHong Kong, Malaysia, Singapore, Thailand, Philippines, Indonesia
-
BayerGlaxoSmithKlineCompletedErectile DysfunctionUnited States, Canada
-
BayerGlaxoSmithKlineCompleted
-
BayerGlaxoSmithKlineCompleted